SCHEMBL4923949

SCHEMBL4923949

O=C(CCCC1CCCN(C(=O)Nc2ccccc2)C1)NO

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 9/20 0.75
HDAC1 Q13547 9/20 0.75
HDAC7 Q8WUI4 9/20 0.75
HDAC11 Q96DB2 9/20 0.75
HDAC8 Q9BY41 9/20 0.75
HDAC6 Q9UBN7 9/20 0.75
HDAC9 Q9UKV0 9/20 0.75
HDAC5 Q9UQL6 9/20 0.75
HDAC3 O15379 8/20 0.75
HDAC2 Q92769 8/20 0.75
HDAC10 Q969S8 8/20 0.75
SMN1; SMN2 Q16637 4/20 0.51
NPC1 O15118 2/20 0.51
TP53 P04637 2/20 0.51
RAB9A P51151 2/20 0.51
HPGD P15428 1/20 0.51
HTT P42858 1/20 0.51
CCR2 P41597 1/20 0.49
KDM4E B2RXH2 2/20 0.48
BRD4 O60885 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4920553 0.86 HDAC4 (1.00) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL4925798 0.80 HDAC3 (0.87) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL4925832 0.77 HDAC1 (0.81) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL5870833 0.75 USP30 (0.51) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL30979855 0.75 EPHX2 (0.65) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL2638492 0.74 HDAC3 (0.64) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL4921200 0.74 HDAC3 (0.78) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL28421952 0.73 EPHX2 (0.68) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL4927435 0.73 HDAC3 (0.76) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL4927500 0.73 HDAC3 (0.76) HDAC4HDAC1HDAC7HDAC11HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207694-A1 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them ROSSI CRISTINA 2008-08-28 US claimed
EP-1868997-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM Menarini International Operations Luxembourg S.A. (LU) 2007-12-26 EP claimed
WO-2006097460-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) 2006-09-21 WO claimed
US-20080207694-A1 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them ROSSI CRISTINA 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207694-A1 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them HDAC1, HDAC8, HDAC9 HDAC4 9/4885HDAC1 1/4885HDAC7 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.